Breast cancer and post-menopausal hormone therapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Best practice & research. Clinical endocrinology & metabolism

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1521-690X(02)00084-2PMID 12763516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic characteristics in breast cancers after hormone replacement therapy

  2005cited by this paper
• Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom)

  2004cited by this paper
• Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

  2004cited by this paper
• Hormone-replacement therapy and breast cancer.

  2002cited by this paper
• Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II)

  2002cited by this paper
• Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?

  2002cited by this paper
• Hormone replacement therapy in relation to breast cancer.

  2002cited by this paper
• In vitro studies of tibolone in breast cells.

  2002cited by this paper
• Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

  2002cited by this paper
• Postmenopausal estrogen and progestin use in relation to breast cancer risk.

  2002cited by this paper
• Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

  2002cited by this paper
• Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  2002cited by this paper
• Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells*

  2002cited by this paper
• Recent trends in breast cancer incidence and mortality

  2002cited by this paper
• The nature and utility of the phytoestrogens: a review of the evidence.

  2002cited by this paper
• Phase III evaluation of fluoxetine for treatment of hot flashes.

  2002cited by this paper
• Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial

  2002cited by this paper
• Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users

  2002cited by this paper
• Hormone replacement therapy and the risk of death from breast cancer: a systematic review.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Physiology of hot flashes

  2001cited by this paper
• Tibolone: a steroid with a tissue-specific mode of action.

  2001cited by this paper
• Raloxifene: Risks and Benefits

  2001cited by this paper
• Serum hormones and the alcohol-breast cancer association in postmenopausal women.

  2001cited by this paper
• Prognosis of breast cancers detected in women receiving hormone replacement therapy.

  2001cited by this paper
• Increased incidence of small and well‐differentiated breast tumours in post‐menopausal women following hormone‐replacement therapy

  2001cited by this paper
• The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.

  2001cited by this paper
• Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.

  2001cited by this paper
• Epidemiology of breast cancer.

  2001cited by this paper
• Hormone replacement in women with a history of breast cancer.

  2001cited by this paper
• Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.

  2001cited by this paper
• Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies.

  2000cited by this paper
• Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle‐aged women

  2000cited by this paper
• Hormonal regulation of apoptosis in breast cells and tissues.

  2000cited by this paper
• Effets des traitements hormonaux substitutifs de la ménopause sur les facteurs pronostiques des cancers du sein

  2000cited by this paper
• [Effects of hormone replacement therapy for menopause on prognostic factors of breast cancer].

  2000cited by this paper
• Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

  2000cited by this paper
• Is Estradiol a Genotoxic Mutagenic Carcinogen ? *

  2000cited by this paper
• Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

  2000cited by this paper
• Is estradiol a genotoxic mutagenic carcinogen?

  2000cited by this paper
• Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement

  1999cited by this paper
• Menopause, HRT and menopausal symptoms.

  1999cited by this paper
• Postmenopausal Estrogen Replacement Therapy Is Associated with Adverse Breast Cancer Prognostic Indices

  1999cited by this paper
• Estrogen Replacement Therapy and Breast Cancer: Analysis of Age of Onset and Tumor Characteristics

  1999cited by this paper
• Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy

  1999cited by this paper
• Hormone replacement therapy and high S phase in breast cancer.

  1999cited by this paper
• Intratumoral levels of estrogens in breast cancer.

  1999cited by this paper
• Hormonal prevention of breast cancer: proposal for a change in paradigm

  1999cited by this paper
• Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer.

  1999cited by this paper
• Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells.

  1999cited by this paper
• Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.

  1999cited by this paper
• Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.

  1999cited by this paper
• Postmenopausal Hormone Replacement Therapy and Gynecological Malignancies

  1999cited by this paper
• Women's health and menopause : risk reduction strategies--improved quality of health

  1999cited by this paper
• Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan.

  1998cited by this paper
• Does Postmenopausal Estrogen Administration Increase the Risk of Breast Cancer? Contributions of Animal, Biochemical, and Clinical Investigative Studies to a Resolution of the Controversy

  1998cited by this paper
• Impact of menopausal hormone‐replacement therapy on clinical and laboratory characteristics of breast cancer

  1998cited by this paper
• Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study.

  1998cited by this paper
• Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast.

  1998cited by this paper
• Progestins and breast cancer.

  1998cited by this paper
• Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.

  1998cited by this paper
• Postmenopausal hormone therapy and mortality.

  1997cited by this paper
• Reproductive Factors, Oral Contraceptive Use, and Risk of Colorectal Cancer

  1997cited by this paper
• Obesity and breast cancer risk.

  1997cited by this paper
• Oestrogens, progestins and breast proliferation.

  1997cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• Hormone replacement and the menopause: a European position paper. Writing Group on Women's Health of the Fondazione Giovanni Lorenzini Medical Science Foundation.

  1997cited by this paper
• Cause‐Specific Mortality in Women Receiving Hormone Replacement Therapy

  1997cited by this paper
• Hormone replacement therapy and the risk of breast cancer. Nested case‐control study in a cohort of Swedish women attending mammography screening

  1997cited by this paper
• Hormone replacement therapy and breast cancer morbidity, mortality and recurrence.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Hormone replacement therapy in patients at high risk of developing breast cancer: The use of a combined risk model

  1997cited by this paper
• Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

  1997cited by this paper
• Hormone replacement therapy and breast cancer.

  1996cited by this paper
• Cancer incidence and mortality in women receiving estrogen and estrogen‐progestin replacement therapy—long‐term follow‐up of a Swedish cohort

  1996cited by this paper
• Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

  1996cited by this paper
• Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1996cited by this paper
• Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.

  1996cited by this paper
• Do Progestogens Reduce The Risk of Breast Cancer? A Review of the Evidence

  1996cited by this paper
• Ovarian ablation in early breast cancer: Overview of the randomised trials

  1996cited by this paper
• Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit

  1996cited by this paper
• Reduced Mortality Associated With Long‐Term Postmenopausal Estrogen Therapy

  1996cited by this paper
• The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Clinical and Biologic Prognostic Factors in Breast Cancer Diagnosed During Postmenopausal Hormone Replacement Therapy

  1995cited by this paper
• The genetics of breast and ovarian cancer.

  1995cited by this paper
• EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECT

  1995cited by this paper
• The Role of Estrogen in Mammary Carcinogenesis a

  1995cited by this paper
• Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Megestrol acetate for the prevention of hot flashes.

  1994cited by this paper
• Carcinoma of the breast in postmenopausal hormone user and nonuser control groups.

  1994cited by this paper
• Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives.

  1994cited by this paper
• The effect of hormone replacement therapy on prognostic indices in women with breast cancer

  1994cited by this paper
• Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle.

  1993cited by this paper
• Reproductive factors and breast cancer.

  1993cited by this paper
• Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.

  1993cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• The prevention of breast cancer through reduced ovarian steroid exposure.

  1992cited by this paper
• Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study.

  1992cited by this paper
• The Relationship Between Breast Cancer Survival and Prior Postmenopausal Estrogen Use

  1992cited by this paper
• The risk of breast cancer after estrogen and estrogen-progestin replacement.

  1989cited by this paper

• Red Clover (Trifolium pratense) as a Source of Phytoestrogens in Beer

  2024cites this paper
• Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?

  2021cites this paper
• Relevance of Steroid Biosynthesis, Metabolism and Transport in Pathophysiology and Drug Discovery

  2019cites this paper
• Hormone Replacement Therapy and Breast Diseases: A Matter of Concern for the Gynecologist

  2019cites this paper
• Estrone-3-Sulfate Stimulates the Proliferation of T47D Breast Cancer Cells Stably Transfected With the Sodium-Dependent Organic Anion Transporter SOAT (SLC10A6)

  2018cites this paper
• A new therapeutic target to facilitate radioiodine treatment of breast cancer

  2017cites this paper
• Chemoprotective Effects of Flaxseed Lignans Enterodiol and Enterolactone in Non-transformed Colonocytes

  2015cites this paper
• Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis

  2015cites this paper
• Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes

  2014cites this paper
• The Effects of Estradiol, Androgens and the Selective Estrogen Modulators: Ospemifene, Raloxifene and Tamoxifen on Explant Cultures of Human Breast Tissue

  2013cites this paper
• Osteoblast response to puerarin-loaded porous titanium surfaces: an in vitro study.

  2012cites this paper
• Estudo de mutações no gene BRCA na população Ashkenazi e não Ashkenazi com histórico para câncer de mama e/ou ovário.

  2011cites this paper
• Promotional Tone in Reviews of Menopausal Hormone Therapy After the Women's Health Initiative: An Analysis of Published Articles

  2011cites this paper
• Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition

  2011cites this paper
• Hormone Replacement Therapy and Breast Cancer: The Situation in Korea.

  2010cites this paper
• Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.

  2009cites this paper
• The effect of low dose hormone therapy on mammographic breast density.

  2009cites this paper
• Preventive effects of Pueraria mirifica on bone loss in ovariectomized rats.

  2008cites this paper
• Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.

  2008cites this paper
• The role of progesterone receptors in breast and endometrial cancer

  2008cites this paper
• Reprint of Oncogenic pathways in hereditary and sporadic breast cancer

  2008cites this paper
• Oncogenic pathways in hereditary and sporadic breast cancer.

  2008cites this paper
• A literature review examining the association between the duration of hormone replacement therapy (HRT) and the risk of breast cancer in women

  2007influential citation
• Low doses in hormone therapy of the menopausal period

  2006cites this paper
• The effect of low dose hormone therapy on mammographic breast density

  2006cites this paper
• TReP-132 Is a Novel Progesterone Receptor Coactivator Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation by Progesterone

  2006cites this paper
• [Menopause - facts and controversies].

  2006influential citation
• Current breast cancer risks of hormone replacement therapy in postmenopausal women

  2006cites this paper
• Sex hormones, anti-hormones and adenocarcinoma of the endometrium

  2005cites this paper
• Postmenopausal hormone therapy and cancer risk

  2005cites this paper
• Premalignant Breast Disease: Anatomic Lesions and Hormonal Associations

  2005cites this paper
• Regulation of E2F-1 gene expression in human breast cancer cells

  2005cites this paper
• Breast cancer versus hormone therapy of the menopausal period

  2005cites this paper
• Postmenopausal hormone therapy and breast cancer: what is the problem?

  2005cites this paper
• Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition.

  2005cites this paper
• Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy?

  2005cites this paper
• Effect of progesterone on DPPC membrane: evidence for lateral phase separation and inverse action in lipid dynamics.

  2005cites this paper
• Applications of chemically-modified cyclodextrins: use of hydroxypropyl-β-cyclodextrin as an enabling excipient for brain targeting, redox-based derivatives of estradiol A review of preclinical and clinical findings

  2004cites this paper
• New Progestogens

  2004cites this paper
• Les traitements hormonaux de la ménopause : passé, présent et avenir

  2004cites this paper
• Exogenous progestagens and the human breast.

  2004cites this paper
• Characterisation of estrone-nucleic acid adducts formed by reaction of 3,4-estrone-o-quinone with 2'-deoxynucleosides/deoxynucleotides using capillary liquid chromatography/electrospray ionization mass spectrometry.

  2004cites this paper
• Use of hormone replacement therapy in Italian women aged 50-70 years.

  2004cites this paper
• Oncogenic pathways in hereditary and sporadic breast cancer.

  2004influential citation
• Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques.

  2004cites this paper
• KONVENTIONELLE HORMONERSATZ- THERAPIE (HRT) UND TIBOLON: WIRKUNG AUF DIE BRUST

  2003influential citation
• Effect of diethylstilbestrol on Ca2+ handling and cell viability in human breast cancer cells.

  2003cites this paper
• Pharmacoepidemiology and drug safety.

  2003cites this paper